Jennifer Green

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc New combination treatments in the management of diabetes: focus on sitagliptin-metformin
    Jennifer Green
    Duke University Medical Center, Department of Medicine, Division of Endocrinology, Durham, North Carolina 27710, USA
    Vasc Health Risk Manag 4:743-51. 2008
  2. ncbi request reprint understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox
    Jennifer B Green
    Associate Professor of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC
    Postgrad Med 126:190-204. 2014
  3. pmc Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
    Mary Elizabeth Cox
    Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition Duke University Medical Center, Durham, NC, USA
    Drug Healthc Patient Saf 2:7-19. 2010
  4. doi request reprint The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety
    Jennifer B Green
    Division of Endocrinology, Duke University Medical Center, Durham, NC 27705, USA
    Postgrad Med 124:54-61. 2012
  5. ncbi request reprint Are sulfonylureas passé?
    Jennifer B Green
    Duke University Medical Center, Division of Endocrinology, DUMC Box 3222, Baker House, Room 280, Durham, NC 27710, USA
    Curr Diab Rep 6:373-7. 2006
  6. ncbi request reprint Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity
    Jennifer B Green
    Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Baker House Room 280, Durham, NC 27710, USA
    Curr Diab Rep 7:369-75. 2007

Collaborators

Detail Information

Publications6

  1. pmc New combination treatments in the management of diabetes: focus on sitagliptin-metformin
    Jennifer Green
    Duke University Medical Center, Department of Medicine, Division of Endocrinology, Durham, North Carolina 27710, USA
    Vasc Health Risk Manag 4:743-51. 2008
    ..Animal studies also suggest that dipeptidyl peptidase-4 inhibitor treatment may help to preserve beta cell mass; however, it is unclear at present whether or not this will prove to be the case in humans...
  2. ncbi request reprint understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox
    Jennifer B Green
    Associate Professor of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC
    Postgrad Med 126:190-204. 2014
    ..Interventions that focus on the management of CV risk factors and glucose lowering with medications that are not cardiotoxic represent an optimal and attainable treatment approach. ..
  3. pmc Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
    Mary Elizabeth Cox
    Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition Duke University Medical Center, Durham, NC, USA
    Drug Healthc Patient Saf 2:7-19. 2010
    ..This review summarizes the available data on the efficacy, safety, and tolerability of these medications...
  4. doi request reprint The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety
    Jennifer B Green
    Division of Endocrinology, Duke University Medical Center, Durham, NC 27705, USA
    Postgrad Med 124:54-61. 2012
    ..Long-term cardiovascular safety trials are currently underway to more fully define and understand the cardiovascular impact of DPP-4 therapy in patients with type 2 diabetes mellitus...
  5. ncbi request reprint Are sulfonylureas passé?
    Jennifer B Green
    Duke University Medical Center, Division of Endocrinology, DUMC Box 3222, Baker House, Room 280, Durham, NC 27710, USA
    Curr Diab Rep 6:373-7. 2006
    ..Fortunately, newer agents such as glimepiride appear less likely to adversely affect the myocardium. These agents can often be used successfully as one component of combination therapy for diabetes management...
  6. ncbi request reprint Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity
    Jennifer B Green
    Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Baker House Room 280, Durham, NC 27710, USA
    Curr Diab Rep 7:369-75. 2007
    ..These medications may well prove to be attractive alternatives or additions to our more established diabetes therapies; however, these drugs have a side-effect profile that may limit their applicability to certain populations...